Prescription peptides, guided by your clinician.

Explore prescription peptides like BPC-157, GHK-Cu, and Semax. A licensed clinician reviews your health history and decides what’s appropriate for you.

*Medications will only be prescribed by a licensed clinician if deemed medically appropriate after individualized consultation. Peptide therapies are not FDA approved. FDA does not review compounded preparations for safety, efficacy, or quality.

What are peptides?

Peptides are short chains of amino acids found naturally in the body. Through Agile, a licensed clinician reviews your health history and determines whether a prescription peptide is right for you.


Explore our peptides →

We make it easy

At Agile, our solutions are simple and accessible.

 

Step 01

Take our quiz

Answer a few simple questions to help us find which program is right for you.

Step 02

Connect with a provider

Connect with one of our healthcare providers to review your medical history and care goals.

Step 03

Start your journey

Access personalized care, resources, and support from professionals and members on our platform.

Individual Peptides

*Peptide therapies are not FDA approved. FDA does not review compounded preparations for safety, efficacy, or quality. For general educational and informational purposes only. This information is not intended to promote any individual medication or to guarantee efficacy or outcomes, and is not a substitute for professional medical advice. All peptides in this program are compounded preparations not evaluated or approved by the FDA. Prescription and program eligibility are not guaranteed and are determined by a licensed healthcare provider after an appropriate medical evaluation. All medication pathways are determined exclusively by licensed healthcare providers following individualized clinical evaluation. Availability varies by clinical appropriateness, federal and state law, and pharmacy. Rx only.

Peptide stacks

Choose up to three peptides you’re curious about. Your clinician will review your selection and recommend what’s right for you.

Which peptides interest you?

2 of 7 selected
BPC-157
Epithalon
GHK-Cu
KPV
MOTS-c
Semax
TB-500

A licensed clinician will review your selections and recommend what’s right for you.

You’re interested in
BPC-157
Epithalon
GHK-Cu
KPV
MOTS-c
Semax
TB-500
This isn’t an order — your clinician will recommend what’s right for you.

Testimonials

R

Ramutu Allen

May 5, 2026

I have been working with Agile Telehealth for my weight management. And I am satisfied with the process so far, the customer service, and the patient portal for ease and transparency. I absolutely appreciate the full scope of blood work required before prescribing anything. I have zero complaints so far. My insurance company’s marketplace connected me to Agile, and I will recommend this company to others as well.
S

Stacy Brady

May 1, 2026

Fast and easy but supportive! If you’re thinking about it…just do it!
D

David Cook

May 11, 2026

April was great to work with and offered solutions to my challenge. Very friendly, knowledgeable, and a problem solver. Her as an advocate is a FAR BETTER process than calling in blind.

FAQ

What is the Peptide Wellness Program?

The program gives patients a prescription-based route to peptides, with every prescription based on an individual evaluation by a licensed clinician. It organizes single-ingredient compounded peptides into six patient goal areas.
Built on clinical rigor, with documented screening and pharmacy quality processes behind every prescription.

The following peptides are available in the program:

  • BPC-157
  • TB-500
  • Epithalon
  • MOTS-c*
  • Semax
  • KPV

*MOTS-c cannot be prescribed alongside GLP-1s.

The program is organized around six patient goal areas, and each one can be offered on its own:

  • Mobility: recovery and musculoskeletal health
  • Gut: digestive health
  • Radiance: skin and hair health
  • Energy: metabolic health and energy
  • Clarity: cognitive health and focus
  • Rhythm: sleep and circadian health
  1. Patients share their health history and goals during intake.
  2. Patients identify which peptides they are interested in.*
  3. A licensed clinician independently evaluates and determines which peptide(s), if any, may be clinically appropriate for the patient.*

*Interest does not determine treatment. Determination occurs after an independent evaluation. The clinician may decline to prescribe.

Yes. The HHS policy covers compounding for individual patients with a valid prescription. In OpenLoop’s Peptide Wellness Program, a licensed clinician evaluates every patient, and prescriptions are issued only when clinically appropriate.

No routine labs required; clinicians order lab testing when indicated based on each patient’s history and needs.

The program includes injectable, oral, topical, and intranasal preparations, which clinicians may consider based on patient needs and preferences.

Dosing is determined by the prescribing clinician. No FDA-approved dosing exists.

No. Under the HHS policy, each product may contain only one covered peptide, so blends and combinations fall outside it. A patient can still be prescribed more than one single-ingredient peptide when their clinician determines it’s clinically appropriate.

MOTS-c cannot be prescribed alongside GLP-1s.

A licensed clinician determines whether any peptide is appropriate based on an individual evaluation. Review of current and past medications, including GLP-1s, is part of each clinician evaluation.

Clinicians determine whether peptide therapy is appropriate for each patient, including patients receiving other treatments.

No. Compounded peptides are not FDA-approved, and the HHS policy doesn’t change that. The policy describes when HHS doesn’t intend to take enforcement action against compounding for individual patients. It isn’t an approval, the peptides’ category status hasn’t changed, HHS can revise the policy, and state rules still apply.

See our full policy blog here for more information.

On Oct. 28, 2026, the U.S. Department of Health and Human Services (HHS) released a draft interim enforcement policy covering six peptides. HHS doesn’t intend to take enforcement action against state-licensed 503A pharmacies, federal facilities, and licensed physicians that compound these peptides for individual patients with a valid prescription, as long as every policy condition is met, such as:

  • A valid prescription for an individual patient
  • Only the specific form and route listed for each peptide
  • One covered peptide per product
  • Ingredients from FDA-registered manufacturers, with a certificate of analysis (CoA)
  • Labeling and reporting requirements for the compounding pharmacy

No. State rules still apply under the HHS policy, and availability depends on state-specific licensure and state board decisions. Those decisions are outside any single company’s control, so where the program is available may change as the policy rolls out.

A synthetic 15-amino-acid peptide whose sequence is derived from a protein found in human gastric juice. It is not FDA-approved for any use.

Most research on BPC-157 comes from laboratory and animal studies. Although stability in gastric juice has been reported, oral absorption has not been established, and no large human randomized controlled trials have been published.

Laboratory and animal studies have examined BPC-157 in the following biological processes:

  • Cell migration
  • New blood vessel formation
  • Collagen deposition

Findings from laboratory and animal studies do not establish that BPC-157 will have any effect on people.

Routes of administration offered:

  • Subcutaneous
  • Intramuscular
  • Oral (Only if bioavailability documentation exists)
  • Topical

Dosing is determined by the prescribing clinician. No FDA-approved dosing exists.

A synthetic peptide that corresponds to a short fragment (amino acids 17–23) of thymosin beta-4, a 43-amino-acid protein the body produces naturally. It is not FDA-approved for any use.

Most research on TB-500 and thymosin beta-4 comes from laboratory and animal studies. Human data are limited and do not establish safety or effectiveness.

Laboratory and animal studies have examined thymosin beta-4 and some of its fragments in the following biological processes:

  • Cell movement (migration)
  • New blood vessel formation

Findings from laboratory and animal studies do not establish that TB-500 will have any effect in people.

Routes of administration offered:

  • Subcutaneous
  • Intramuscular

Dosing is determined by the prescribing clinician. No FDA-approved dosing exists.

A synthetic four-amino-acid peptide developed from epithalamin, an extract of the pineal gland. It is not FDA-approved for any use.

Most research on Epithalon comes from a single research group. Human data are limited and do not establish safety or effectiveness.

Laboratory and animal studies have examined Epithalon in the following biological process:

  • Telomerase, an enzyme involved in cell division

Routes of administration offered:

  • Subcutaneous
  • Intramuscular

Prescribed in intermittent courses. Dosing and course length are determined by the prescribing clinician. No FDA-approved dosing exists.

A 16-amino-acid peptide encoded within mitochondrial DNA, first described in 2015. It is not FDA-approved for any use. FDA has not identified human exposure data for drug products containing MOTS-c.

Research on MOTS-c comes primarily from laboratory and animal studies. Human data are limited and do not establish safety or effectiveness.

Laboratory and animal studies have examined MOTS-c in the following biological processes:

  • AMPK signaling
  • Mitochondrial biology

Clinical considerations: MOTS-c may affect blood sugar levels. Low blood sugar is a possible risk, especially for people taking diabetes or other glucose-lowering medications.

Routes of administration offered:

  • Subcutaneous
  • Intramuscular

Not prescribed alongside GLP-1 medications.

Dosing is determined by the prescribing clinician. No FDA-approved dosing exists.

Talk to a licensed clinician.

Complete a short online intake to see if peptides are right for you.​